Ab Februar vermutlich erstmalig verfügbar: Brinsupri. Warum das so cool ist? Die Non-CF-Bronchiektasen (also Bronchiektasen ohne Mukoviszidose) konnte bislang eigentlich nur symptomatisch behandelt werden
www.pharmazeutische-zeitung.de/erstes-medik...
www.pharmazeutische-zeitung.de/erstes-medik...
Brensocatib : Erstes Medikament für chronische Lungenkrankheit zugelassen
Die EU-Kommission hat mit Brensocatib erstmals ein Arzneimittel zur Behandlung von Bronchiektasen, die nicht durch zystische Fibrose verursacht werden, zug...
www.pharmazeutische-zeitung.de
January 27, 2026 at 7:20 PM
Ab Februar vermutlich erstmalig verfügbar: Brinsupri. Warum das so cool ist? Die Non-CF-Bronchiektasen (also Bronchiektasen ohne Mukoviszidose) konnte bislang eigentlich nur symptomatisch behandelt werden
www.pharmazeutische-zeitung.de/erstes-medik...
www.pharmazeutische-zeitung.de/erstes-medik...
"Ertster Wirkstoff gegen COPD und Mukoviszidose gefunden"
www.apotheke-adhoc.de/nachrichten/...
#TeamWissenschaft
www.apotheke-adhoc.de/nachrichten/...
#TeamWissenschaft
Erster Wirkstoff gegen COPD und Mukoviszidose gefunden | APOTHEKE ADHOC
Brensocatib könnte der erste Wirkstoff sein, der chronische Bronchiektasen ursächlich behandeln kann. In der bislang größten Phase-3-Studie zur Erkrankung zeigte der Wirkstoff signifikante Verbesserun...
www.apotheke-adhoc.de
May 4, 2025 at 2:35 PM
"Ertster Wirkstoff gegen COPD und Mukoviszidose gefunden"
www.apotheke-adhoc.de/nachrichten/...
#TeamWissenschaft
www.apotheke-adhoc.de/nachrichten/...
#TeamWissenschaft
www.gov.uk/government/n...
#bronchiectasis
This is the drug we have been waiting for- actual treatment for bronchiectasis.
Now a wait for funding decisions, but this is an enormous step forward
Thank you to @profjdchalmers.bsky.social and team for all your work!
#bronchiectasis
This is the drug we have been waiting for- actual treatment for bronchiectasis.
Now a wait for funding decisions, but this is an enormous step forward
Thank you to @profjdchalmers.bsky.social and team for all your work!
Brensocatib licensed as the first medicine specifically designed to treat non-cystic fibrosis bronchiectasis in patients 12 years and older
As with any medicine, the MHRA will keep the safety and effectiveness of brensocatib under close review.
www.gov.uk
February 25, 2026 at 12:02 PM
www.gov.uk/government/n...
#bronchiectasis
This is the drug we have been waiting for- actual treatment for bronchiectasis.
Now a wait for funding decisions, but this is an enormous step forward
Thank you to @profjdchalmers.bsky.social and team for all your work!
#bronchiectasis
This is the drug we have been waiting for- actual treatment for bronchiectasis.
Now a wait for funding decisions, but this is an enormous step forward
Thank you to @profjdchalmers.bsky.social and team for all your work!
Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, may lower the rate of pulmonary exacerbations in patients with bronchiectasis. Findings from the ASPEN phase 3 trial are summarized in a short video. nej.md/4jhMNPA
#MedSky #PedSky #PulmSky
#MedSky #PedSky #PulmSky
April 27, 2025 at 7:01 PM
Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, may lower the rate of pulmonary exacerbations in patients with bronchiectasis. Findings from the ASPEN phase 3 trial are summarized in a short video. nej.md/4jhMNPA
#MedSky #PedSky #PulmSky
#MedSky #PedSky #PulmSky
Is there a better thing for a physician scientist than to have an impact on our patients - to take a previously ignored and hopeless disease and make it treatable?
Kudos Prof Chalmers ! What an amazing achievment!!! also 👏🏼to all #Aspen investigators 👏🏼
#CureBronchoiectasis
#ScienceMatters
Kudos Prof Chalmers ! What an amazing achievment!!! also 👏🏼to all #Aspen investigators 👏🏼
#CureBronchoiectasis
#ScienceMatters
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis | NEJM
In bronchiectasis, neutrophilic inflammation is associated with an increased risk
of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor
of dipeptidyl peptidase 1 (DPP...
www.nejm.org
April 25, 2025 at 10:09 PM
Is there a better thing for a physician scientist than to have an impact on our patients - to take a previously ignored and hopeless disease and make it treatable?
Kudos Prof Chalmers ! What an amazing achievment!!! also 👏🏼to all #Aspen investigators 👏🏼
#CureBronchoiectasis
#ScienceMatters
Kudos Prof Chalmers ! What an amazing achievment!!! also 👏🏼to all #Aspen investigators 👏🏼
#CureBronchoiectasis
#ScienceMatters
Adam T. Hill, MD, describes the scientific foundations of a phase 3 study of brensocatib for the treatment of bronchiectasis.
Read the editorial “Defanging the Neutrophil to Treat Bronchiectasis”: nej.md/4cANv89
#MedSky #ScienceSky
Read the editorial “Defanging the Neutrophil to Treat Bronchiectasis”: nej.md/4cANv89
#MedSky #ScienceSky
April 25, 2025 at 7:17 PM
Adam T. Hill, MD, describes the scientific foundations of a phase 3 study of brensocatib for the treatment of bronchiectasis.
Read the editorial “Defanging the Neutrophil to Treat Bronchiectasis”: nej.md/4cANv89
#MedSky #ScienceSky
Read the editorial “Defanging the Neutrophil to Treat Bronchiectasis”: nej.md/4cANv89
#MedSky #ScienceSky
Neutrophil-targeting drug seeks first approval in an inflammatory lung disease www.nature.com/articles/d41...
Insmed’s DPP1 inhibitor brensocatib could become the first drug to secure an approval for bronchiectasis, and is in trials for other inflammatory diseases. Read more in our news article
Insmed’s DPP1 inhibitor brensocatib could become the first drug to secure an approval for bronchiectasis, and is in trials for other inflammatory diseases. Read more in our news article
June 18, 2025 at 2:35 PM
Neutrophil-targeting drug seeks first approval in an inflammatory lung disease www.nature.com/articles/d41...
Insmed’s DPP1 inhibitor brensocatib could become the first drug to secure an approval for bronchiectasis, and is in trials for other inflammatory diseases. Read more in our news article
Insmed’s DPP1 inhibitor brensocatib could become the first drug to secure an approval for bronchiectasis, and is in trials for other inflammatory diseases. Read more in our news article
In the ASPEN phase 3 trial involving patients with noncystic fibrosis bronchiectasis, the rate of pulmonary exacerbations over a 52-week period was lower with brensocatib (10 mg or 25 mg per day) than with placebo. Full trial results and Research Summary: nej.md/4lBHwUr
#MedSky #PulmSky
#MedSky #PulmSky
April 29, 2025 at 1:04 PM
In the ASPEN phase 3 trial involving patients with noncystic fibrosis bronchiectasis, the rate of pulmonary exacerbations over a 52-week period was lower with brensocatib (10 mg or 25 mg per day) than with placebo. Full trial results and Research Summary: nej.md/4lBHwUr
#MedSky #PulmSky
#MedSky #PulmSky
Neutrophil-targeted drug brensocatib secures first FDA approval for inflammatory lung disease nature.com/articles/d41...
The first-in-class DPP1 inhibitor is anticipated to have annual sales of >US$4 billion. Read more about the DPP1 inhibitor pipeline here nature.com/articles/d41...
The first-in-class DPP1 inhibitor is anticipated to have annual sales of >US$4 billion. Read more about the DPP1 inhibitor pipeline here nature.com/articles/d41...
August 12, 2025 at 4:54 PM
Neutrophil-targeted drug brensocatib secures first FDA approval for inflammatory lung disease nature.com/articles/d41...
The first-in-class DPP1 inhibitor is anticipated to have annual sales of >US$4 billion. Read more about the DPP1 inhibitor pipeline here nature.com/articles/d41...
The first-in-class DPP1 inhibitor is anticipated to have annual sales of >US$4 billion. Read more about the DPP1 inhibitor pipeline here nature.com/articles/d41...
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis | New England Journal of Medicine www.nejm.org/doi/full/10....
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis | NEJM
In bronchiectasis, neutrophilic inflammation is associated with an increased risk
of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor
of dipeptidyl peptidase 1 (DPP...
www.nejm.org
May 9, 2025 at 2:20 AM
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis | New England Journal of Medicine www.nejm.org/doi/full/10....
Broad Immunomodulatory Effects of the Dipeptidyl Peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial
A novel treatment for bronchiectasis
@profjdchalmers.bsky.social
www.atsjournals.org/doi/full/10....
A novel treatment for bronchiectasis
@profjdchalmers.bsky.social
www.atsjournals.org/doi/full/10....
May 4, 2025 at 9:50 PM
Broad Immunomodulatory Effects of the Dipeptidyl Peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial
A novel treatment for bronchiectasis
@profjdchalmers.bsky.social
www.atsjournals.org/doi/full/10....
A novel treatment for bronchiectasis
@profjdchalmers.bsky.social
www.atsjournals.org/doi/full/10....
BRINSUPRI (brensocatib) approved!!
Let’s keep doing the work— airway clearance, exercise, nutritious eating, moving toward a healthy weight zone and stress management to stay strong💪🏽💪🏽. Help is on the way!🌿
#bronchiectasis
Let’s keep doing the work— airway clearance, exercise, nutritious eating, moving toward a healthy weight zone and stress management to stay strong💪🏽💪🏽. Help is on the way!🌿
#bronchiectasis
August 12, 2025 at 5:16 PM
BRINSUPRI (brensocatib) approved!!
Let’s keep doing the work— airway clearance, exercise, nutritious eating, moving toward a healthy weight zone and stress management to stay strong💪🏽💪🏽. Help is on the way!🌿
#bronchiectasis
Let’s keep doing the work— airway clearance, exercise, nutritious eating, moving toward a healthy weight zone and stress management to stay strong💪🏽💪🏽. Help is on the way!🌿
#bronchiectasis
Thanks to Emma Johnson, MBBS, MSc, PhD, for contributing to the May issue
Broad Immunomodulatory Effects of the DPP1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial
@profjdchalmers.bsky.social
www.atsjournals.org/doi/10.1164/...
Broad Immunomodulatory Effects of the DPP1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial
@profjdchalmers.bsky.social
www.atsjournals.org/doi/10.1164/...
May 4, 2025 at 9:59 PM
Thanks to Emma Johnson, MBBS, MSc, PhD, for contributing to the May issue
Broad Immunomodulatory Effects of the DPP1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial
@profjdchalmers.bsky.social
www.atsjournals.org/doi/10.1164/...
Broad Immunomodulatory Effects of the DPP1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial
@profjdchalmers.bsky.social
www.atsjournals.org/doi/10.1164/...
‼️Wednesday, 9/10 3pt ET ‼️
Join the #Bronchiectasis and #NTM
Association with special guest Dr. Mark Metersky (Director, Bronchiectasis Center, University of Connecticut) as he breaks down the latest updates on Brensocatib (Brinsupri)
tinyurl.com/mpw4e4ve
Join the #Bronchiectasis and #NTM
Association with special guest Dr. Mark Metersky (Director, Bronchiectasis Center, University of Connecticut) as he breaks down the latest updates on Brensocatib (Brinsupri)
tinyurl.com/mpw4e4ve
September 8, 2025 at 2:23 PM
‼️Wednesday, 9/10 3pt ET ‼️
Join the #Bronchiectasis and #NTM
Association with special guest Dr. Mark Metersky (Director, Bronchiectasis Center, University of Connecticut) as he breaks down the latest updates on Brensocatib (Brinsupri)
tinyurl.com/mpw4e4ve
Join the #Bronchiectasis and #NTM
Association with special guest Dr. Mark Metersky (Director, Bronchiectasis Center, University of Connecticut) as he breaks down the latest updates on Brensocatib (Brinsupri)
tinyurl.com/mpw4e4ve
Couldn’t sleep last night processing all the fantastic news for our #bronchiectasis & #NTM community. Thank you Dr Daley & the NJH team for a fabulous patient conference‼️ #BRINSUPRI #brensocatib #AirwayClearance #CareCenters
September 14, 2025 at 3:23 PM
Couldn’t sleep last night processing all the fantastic news for our #bronchiectasis & #NTM community. Thank you Dr Daley & the NJH team for a fabulous patient conference‼️ #BRINSUPRI #brensocatib #AirwayClearance #CareCenters
New in the April 24, 2025, issue of NEJM:
DPP-1 Inhibitor Brensocatib in Bronchiectasis (ASPEN phase 3 trial) nej.md/4lBHwUr
Baloxavir in Preventing Influenza Transmission (CENTERSTONE phase 3b trial) nej.md/4j78IZE
#MedSky
DPP-1 Inhibitor Brensocatib in Bronchiectasis (ASPEN phase 3 trial) nej.md/4lBHwUr
Baloxavir in Preventing Influenza Transmission (CENTERSTONE phase 3b trial) nej.md/4j78IZE
#MedSky
April 24, 2025 at 1:06 PM
New in the April 24, 2025, issue of NEJM:
DPP-1 Inhibitor Brensocatib in Bronchiectasis (ASPEN phase 3 trial) nej.md/4lBHwUr
Baloxavir in Preventing Influenza Transmission (CENTERSTONE phase 3b trial) nej.md/4j78IZE
#MedSky
DPP-1 Inhibitor Brensocatib in Bronchiectasis (ASPEN phase 3 trial) nej.md/4lBHwUr
Baloxavir in Preventing Influenza Transmission (CENTERSTONE phase 3b trial) nej.md/4j78IZE
#MedSky
"Ertster Wirkstoff gegen COPD und Mukoviszidose gefunden"
www.apotheke-adhoc.de/nachrichten/...
#TeamWissenschaft
www.apotheke-adhoc.de/nachrichten/...
#TeamWissenschaft
Erster Wirkstoff gegen COPD und Mukoviszidose gefunden | APOTHEKE ADHOC
Brensocatib könnte der erste Wirkstoff sein, der chronische Bronchiektasen ursächlich behandeln kann. In der bislang größten Phase-3-Studie zur Erkrankung zeigte der Wirkstoff signifikante Verbesserun...
www.apotheke-adhoc.de
May 4, 2025 at 3:42 PM
In the ASPEN phase 3 trial involving patients with noncystic fibrosis bronchiectasis, the rate of pulmonary exacerbations over a 52-week period was lower with brensocatib (10 mg or 25 mg per day) than with placebo. Full trial results: nej.md/4lBHwUr
#MedSky #PedSky #PulmSky
#MedSky #PedSky #PulmSky
April 25, 2025 at 4:02 PM
In the ASPEN phase 3 trial involving patients with noncystic fibrosis bronchiectasis, the rate of pulmonary exacerbations over a 52-week period was lower with brensocatib (10 mg or 25 mg per day) than with placebo. Full trial results: nej.md/4lBHwUr
#MedSky #PedSky #PulmSky
#MedSky #PedSky #PulmSky
Did you know that a brand new treatment for bronchiectasis – the first ever treatment developed specifically for this condition – could be available within the next few years?
October 17, 2025 at 12:29 PM
Did you know that a brand new treatment for bronchiectasis – the first ever treatment developed specifically for this condition – could be available within the next few years?
Temporal N-terminomics analysis reveals proteome remodeling following brensocatib-mediated cathepsin C inhibition in promyeloblast cells https://www.biorxiv.org/content/10.64898/2026.09.03.748759v1
September 7, 2026 at 8:45 PM
Temporal N-terminomics analysis reveals proteome remodeling following brensocatib-mediated cathepsin C inhibition in promyeloblast cells https://www.biorxiv.org/content/10.64898/2026.09.03.748759v1
Want to know about all the drugs the @fda.gov approved in August? Check them out here!
sliversofscience.com/fda-approval...
sliversofscience.com/fda-approval...
FDA approvals: August 2025 - Slivers of Science
This month the FDA approved 4 new drugs. Modeyso (dordaviprone) Hernexeos (zongertinib) Brinsupri (brensocatib) Dawnzera (donidalorsen)
sliversofscience.com
August 31, 2025 at 8:48 PM
Want to know about all the drugs the @fda.gov approved in August? Check them out here!
sliversofscience.com/fda-approval...
sliversofscience.com/fda-approval...
Phase 3 Trial of the DPP-1 Inhibitor #Brensocatib in #Bronchiectasis
Interesting that this study performed during the height of the COVID19 pandemic with probably reduced incidence of exacerbations in the placebo group, still shows a stat. significant signal of benefit.
www.nejm.org/doi/full/10....
Interesting that this study performed during the height of the COVID19 pandemic with probably reduced incidence of exacerbations in the placebo group, still shows a stat. significant signal of benefit.
www.nejm.org/doi/full/10....
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis | NEJM
In bronchiectasis, neutrophilic inflammation is associated with an increased risk
of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor
of dipeptidyl peptidase 1 (DPP...
www.nejm.org
April 26, 2025 at 7:23 AM
Phase 3 Trial of the DPP-1 Inhibitor #Brensocatib in #Bronchiectasis
Interesting that this study performed during the height of the COVID19 pandemic with probably reduced incidence of exacerbations in the placebo group, still shows a stat. significant signal of benefit.
www.nejm.org/doi/full/10....
Interesting that this study performed during the height of the COVID19 pandemic with probably reduced incidence of exacerbations in the placebo group, still shows a stat. significant signal of benefit.
www.nejm.org/doi/full/10....
Editorial: Brensocatib in Bronchiectasis — A New Sheriff in Town? nej.md/4jDIaz7
Science behind the Study: Defanging the Neutrophil to Treat Bronchiectasis nej.md/4cANv89
Science behind the Study: Defanging the Neutrophil to Treat Bronchiectasis nej.md/4cANv89
April 25, 2025 at 4:02 PM
Editorial: Brensocatib in Bronchiectasis — A New Sheriff in Town? nej.md/4jDIaz7
Science behind the Study: Defanging the Neutrophil to Treat Bronchiectasis nej.md/4cANv89
Science behind the Study: Defanging the Neutrophil to Treat Bronchiectasis nej.md/4cANv89
Exciting results from the ASPEN trial. Lower rates of pulmonary exacerbations in BE and delayed decline of lung function with higher-dose brensocatib.
#pulmsky
#pulmsky
New in the April 24, 2025, issue of NEJM:
DPP-1 Inhibitor Brensocatib in Bronchiectasis (ASPEN phase 3 trial) nej.md/4lBHwUr
Baloxavir in Preventing Influenza Transmission (CENTERSTONE phase 3b trial) nej.md/4j78IZE
#MedSky
DPP-1 Inhibitor Brensocatib in Bronchiectasis (ASPEN phase 3 trial) nej.md/4lBHwUr
Baloxavir in Preventing Influenza Transmission (CENTERSTONE phase 3b trial) nej.md/4j78IZE
#MedSky
April 25, 2025 at 2:27 PM
Exciting results from the ASPEN trial. Lower rates of pulmonary exacerbations in BE and delayed decline of lung function with higher-dose brensocatib.
#pulmsky
#pulmsky